This study, called Beamion LUNG-3, is looking at whether a drug called zongertinib can help people with a specific type of lung cancer. You might be able to join if you have non-small cell lung cancer (NSCLC) that has been completely removed by surgery, is Stage II-IIIB, and has a HER2 gene mutation. Zongertinib is a targeted therapy, meaning it focuses on specific changes in cancer cells. Participants will receive either zongertinib or standard treatment, which could include other approved immunotherapies like pembrolizumab, atezolizumab, durvalumab, or nivolumab, or observation. The main goal is to see if zongertinib helps people live longer without their cancer returning (disease-free survival). The study is planning to enroll 400 people, but its current status is unclear.

Study design

This is a global, randomized, open-label study, meaning participants are randomly assigned to a treatment group and both you and your doctors will know which treatment you are receiving. It plans to include 400 participants.

What's involved

Participants will take zongertinib orally once daily for up to 3 years, or receive standard treatment which may include an approved adjuvant immunotherapy or observation. You must have signed a consent form and be able to use effective birth control if you are a woman of childbearing potential.

Compensation

Not stated in the trial record.

Follow-up

The main outcome of the study, disease-free survival, will be measured for up to 8 years and 5 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.